Accueil / Communiqués / Oragenics Inc. to Attend the Roth Capital 31st Annual Growth Conference March 17 – 19, 2019

Oragenics Inc. to Attend the Roth Capital 31st Annual Growth Conference March 17 – 19, 2019

Friday, March 15th 2019 at 4:00am UTC

TAMPA, Fla.–(BUSINESS WIRE)– Oragenics, Inc. (NYSE American: OGEN), a leader in the development of
new antibiotics against infectious diseases and effective treatments for
oral mucositis (“OM”), today announced that Alan Joslyn, Ph.D.,
President and CEO of Oragenics, Inc. will attend the Roth Capital 31st
Annual Growth Conference. The conference will be held at the
Ritz-Carlton Hotel in Laguna Nigel, CA.

Dr. Joslyn will be available for one-on-one meetings at the conference
on March 18 and March 19.

About Oragenics, Inc.

We are focused on becoming a leader in novel antibiotics against
infectious disease and on developing effective treatments for oral
mucositis. Oragenics, Inc. has established two exclusive worldwide
channel collaborations with Intrexon Corporation and its subsidiaries.
The collaborations allows Oragenics to accelerate the development of
much needed new antibiotics that can work against resistant strains of
bacteria and the development of biotherapeutics for oral mucositis and
other diseases and conditions of the oral cavity, throat, and esophagus.

For more information about Oragenics, please visit www.oragenics.com.

Safe Harbor Statement: Under the Private Securities Litigation
Reform Act of 1995: This release includes forward-looking statements
that reflect management’s current views with respect to future events
and performance. These forward-looking statements are based on
management’s beliefs and assumptions and information currently
available. The words “ believe,” “ expect,” “ anticipate,” “ intend,” “
estimate,” “ project” and similar expressions that do not relate solely
to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they
are subject to a variety of risks, uncertainties, and other factors that
could cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are not
limited to, risks and uncertainties described in our filings with the
U.S. Securities and Exchange Commission. Oragenics assumes no
responsibility to update any forward-looking statements contained in
this press release or with respect to the matters described herein.

Contacts

Oragenics, Inc.
Corporate:
Michael Sullivan,
813-286-7900
Chief Financial Officer
msullivan@oragenics.com
or
Investors:
John
Marco
Managing Director
CORE IR
310-819-2948
johnm@coreir.com
Media:
Jules
Abraham
CORE IR
917-885-7378
julesa@coreir.com

Source: Oragenics, Inc.


Voir aussi

Innovations in Artificial Intelligence, Blockchain, Quantum Computing, Robots, and Catalysts, 2019 Study – ResearchAndMarkets.com

Friday, March 22nd 2019 at 3:01pm UTC DUBLIN–(BUSINESS WIRE)– The « Innovations in Artificial Intelligence, Blockchain, …